Autres langues Vir Biotechnology, Inc.

Actions

VIR

US92764N1028

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
8,23 ^USD	+7,86%		+3,52%	-18,19%

26/04	Cytokinetics nomme Sung Lee au poste de directeur financier	MT
18/04	Vir Biotechnology, Inc. annonce la démission de Sung Lee en tant que vice-président exécutif, à compter du 3 mai 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cytokinetics Appoints Sung Lee as CFO	26/04
Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Chief Financial Officer, Effective May 3, 2024	18/04
Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Executive Vice President, effective May 3, 2024	18/04
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors	18/04
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024	11/04
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results	25/03
Vir Biotechnology Completes Enrollment in Phase 2 Chronic Hepatitis Delta Trial Ahead of Schedule	05/03
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule	05/03
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule	05/03
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences	26/02
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences	23/02
Vir Biotechnology's Q4 Loss Widens, Revenue Declines	23/02
Vir Biotechnology, GSK Terminate Collaboration on Flu	22/02
Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q4 Revenue $16.8M, vs. Street Est of $6.55M	22/02
Vir Biotechnology, Inc. and Glaxo Wellcome UK Limited Mutually Agrees to Terminate Collaboration on the Influenza Program Under the DCA	22/02
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results	22/02
Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	22/02
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer	20/02
Vir Biotechnology, Inc. Announces Phil Pang Will Step Down as Chief Medical Officer	20/02
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024	01/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Vir Biotechnology, Inc.

Actions

VIR

US92764N1028

Autres langues

Filtres